Highlights

  • CurveBeam AI is prioritising a fresh operational milestone.
  • The latest update shifts attention to operating delivery.
  • Management faces financial and practical hurdles in delivering its plan.
  • Investors will track funding, deadlines and evidence of progress.

CurveBeam AI (ASX:CVB) has secured US clearance for bone-density software while preparing for a possible China launch. Regulatory progress expands the product opportunity without fixing current losses. Commercial adoption and fresh funding remain the immediate tests. For shareholders, the distinction is between a headline milestone and the harder work of translating it into durable value.

The Numbers Behind the Shift

CurveBeam AI Limited listed on the ASX on 23 August 2023 and is classified in the Health Care sector, within health care equipment and services. The ASX describes it as developing, Manufacturing and selling specialised medical imaging scanners and software.

Its products include HiRise, a weight-bearing CT system, and PedCAT, a paediatric imaging system. It has more than 70 employees across Melbourne and Hatfield, Pennsylvania, where its global operations are based.

What Changes on the Ground

The cleared technology estimates bone mineral density from multidetector CT supine scans already taken during orthopaedic evaluation. The company says this could provide anatomical, alignment and bone-quality information from a single examination, and could reduce the need for separate DXA scans. The announcement cites a study of pandemic-era delays in which the mean wait for conventional bone density assessment was 88.8 days, which illustrates the workflow problem the company wants to address.

Management plans to extend the capability to weight-bearing scans on HiRise and to launch a software-as-a-service Revenue model once HiRise is cleared. It also intends to integrate the technology into robotic-assisted surgical planning. Those steps are plans, not approvals.

Cash, Capital and the Trade-Off

For FY26 revenue fell 28 per cent to A$8.67 million from A$12.10 million. The net loss widened to A$18.83 million from A$16.84 million, and operating cash outflow was A$13.01 million. Net Assets were A$27.78 million at 30 June 2026, down from A$35.11 million a year earlier, and net tangible assets per share were negative at 1.62 cents.

The auditor included a material uncertainty about the company's ability to continue as a going concern. The report ties that to completing regulatory clearance for an enhanced HiRise in China and securing additional funding.

The Milestones That Matter

On 17 September 2026 the company announced that an oversubscribed shortfall offer and Placement raised A$1.75 million at A$0.018 per share, taking the combined raising to A$7.36 million with an earlier placement and share purchase plan. Separately, the share purchase plan issued 33,675,039 shares worth A$606,150.70, and Spark Plus Pte Ltd was engaged as corporate adviser to Fill the shortfall. Proceeds are earmarked for sales and marketing, including China launch preparation, research and development, Supply chain costs and working capital.

The company has binding agreements with Shandong WeiYing for exclusive China rights, including up to A$10 million of Equity Investment across milestones. The first A$4 million arrived in February 2026. China clearance by the National Medical Products Administration is expected in the first half of FY27, and would trigger a further A$1 million.